The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Selective JAK3 Inhibitors with a Covalent Reversible Binding Mode Targeting a New Induced Fit Binding Pocket
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Ibrutinib, which contains a relatively weakly-reactive acrylamide warhead that covalently binds Bruton's tyrosine kinase C481, and FM-381, which contains a cyano-acrylamide warhead that inhibits JAK3 by reversible covalent binding to C909, do not react with the La antigen reporter protein (Figure 5) (Forster et al., 2016; Honigberg et al., 2010).”
From ALARM NMR for HTS Triage and Chemical Probe Validation (2018) · cites this paper as Forster et al., 2016
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Covalent docking of large libraries for the discovery of chemical probes
London, N., Miller, R. M., Krishnan, S., Uchida, K., Irwin, J. J., Eidam, O., Gibold, L., Cimermančič, P., Bonnet, R., Shoichet, B. K., et al. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1666 · Cited by 274 · cited 1×
“Published by Elsevier Ltd. 1335 er the CC BY license (http://creativecommons.org/licenses/by/4.0/). was successfully applied by London et al. (2014) to obtain JAK3 inhibitors with reasonable in vitro activity and isoform selectivity, but without a proven cellular activity and kinome-wide…”
MethodInfluentialDevelopment of Selective Covalent Janus Kinase 3 Inhibitors
Tan, L., Akahane, K., McNally, R., Reyskens, K. M. S. E., Ficarro, S. B., Liu, S., Herter-Sprie, G. S., Koyama, S., Pattison, M. J., Labella, K., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00710 · Cited by 122
Tricyclic Covalent Inhibitors Selectively Target Jak3 through an Active Site Thiol
Goedken, E. R., Argiriadi, M. A., Banach, D. L., Fiamengo, B. A., Foley, S. E., Frank, K. E., George, J. S., Harris, C. M., Hobson, A. D., Ihle, D. C., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.595181 · Cited by 101
Research works printed but not linked: 18
- Bauer, 2014, A direct enzyme-linked immunosorbent assay (ELISA) for the quantitative evaluation of Janus Kinase 3 (JAK3) inhibitors, Anal. Methods, 6, 8817, 10.1039/C4AY01589D · doi:10.1039/c4ay01589d
- Chrencik, 2010, Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6, J. Mol. Biol., 400, 413, 10.1016/j.jmb.2010.05.020 · DOI · Paper page
- Flanagan, 2010, Discovery of CP-690'550: a potent and selective Janus Kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection, J. Med. Chem., 53, 8468, 10.1021/jm1004286 · DOI · Paper page
- Gehringer, 2014, Design and synthesis of tricyclic JAK3 inhibitors with picomolar affinities as novel molecular probes, ChemMedChem, 9, 277, 10.1002/cmdc.201300520 · DOI
- Ghoreschi, 2009, Selectivity and therapeutic inhibition of kinases: to be or not to be?, Nat. Immunol., 10, 356, 10.1038/ni.1701 · DOI · Paper page
- Ghoreschi, 2011, Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550), J. Immunol., 186, 4234, 10.4049/jimmunol.1003668 · DOI · Paper page
- Haan, 2011, Jak1 has a dominant role over jak3 in signal transduction through gamma-c-containing cytokine receptors, Chem. Biol., 18, 314, 10.1016/j.chembiol.2011.01.012 · DOI · Paper page
- Knapp, 2013, A public-private partnership to unlock the untargeted kinome, Nat. Chem. Biol., 9, 3, 10.1038/nchembio.1113 · DOI
- Liu, 2013, Developing irreversible inhibitors of the protein kinase cysteinome, Chem. Biol., 20, 146, 10.1016/j.chembiol.2012.12.006 · DOI · Paper page
- Muller, 2015, The ins and outs of selective kinase inhibitor development, Nat. Chem. Biol., 11, 818, 10.1038/nchembio.1938 · DOI · Paper page
- Pesu, 2005, Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs, Immunol. Rev., 203, 127, 10.1111/j.0105-2896.2005.00220.x · DOI
- Robers, 2015, Target engagement and drug residence time can be observed in living cells with BRET, Nat. Commun., 6, 10091, 10.1038/ncomms10091 · DOI · Paper page
- Serafimova, 2012, Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles, Nat. Chem. Biol., 8, 471, 10.1038/nchembio.925 · DOI · Paper page
- Singh, 2010, Targeted covalent drugs of the kinase family, Curr. Opin. Chem. Biol., 14, 475, 10.1016/j.cbpa.2010.06.168 · DOI · Paper page
- Smith, 2016, Essential biphasic role for JAK3 catalytic activity in IL-2 receptor signaling, Nat. Chem. Biol., 12, 373, 10.1038/nchembio.2056 · DOI
- Thoma, 2011, Identification of a potent Janus kinase 3 inhibitor with high selectivity within the Janus kinase family, J. Med. Chem., 54, 284, 10.1021/jm101157q · DOI
- Thoma, 2014, Selective inhibitors of the Janus kinase Jak3—Are they effective?, Bioorg. Med. Chem. Lett., 24, 4617, 10.1016/j.bmcl.2014.08.046 · DOI
- Thorarensen, 2014, ATP-mediated kinome selectivity: the missing link in understanding the contribution of individual jak kinase isoforms to cellular signaling, ACS Chem. Biol., 9, 1552, 10.1021/cb5002125 · DOI
Cited by
Kinase inhibitors: the road ahead
Ferguson, F. M., & Gray, N. S. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.21 · Cited by 1,009
Trends in kinase drug discovery: targets, indications and inhibitor design
Attwood, M. M., Fabbro, D., Sokolov, A. V., Knapp, S., & Schiöth, H. B. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00252-y · Cited by 779
Self-citationGehringer, M., & Laufer, S. A. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01153 · Cited by 714
Self-citationA Comprehensive Overview of Globally Approved JAK Inhibitors
Shawky, A. M., Almalki, F. A., Abdalla, A. N., Abdelazeem, A. H., & Gouda, A. M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14051001 · Cited by 349
Advances in covalent kinase inhibitors
Abdeldayem, A., Raouf, Y. S., Constantinescu, S. N., Moriggl, R., & Gunning, P. T. (2020) · Chemical Society Reviews · doi:10.1039/c9cs00720b · Cited by 317
Metadata
- Authors
- Forster, M., Chaikuad, A., Bauer, S. M., Holstein, J., Robers, M. B., Corona, C. R., Gehringer, M., Pfaffenrot, E., Ghoreschi, K., Knapp, S., & Laufer, S. A.
- Venue
- Cell Chemical Biology
- Publisher
- Elsevier BV
- Published
- 2016-11
- Volume
- 23
- Issue
- 11
- Pages
- 1335-1340
- ISSN
- 2451-9456
- Cited by
- 126
- References
- 3
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Funders
- Canada Foundation for Innovation
- Takeda Pharmaceutical Company
- Deutsche Forschungsgemeinschaft (SFB TR156)
- Genome Canada
- Innovative Medicines Initiative
- Wellcome Trust (092809/Z/10/Z)
- Pfizer
- Ontario Genomics Institute
- Ontario Ministry of Economic Development and Innovation
- Boehringer Ingelheim
- Janssen Biotech
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.